Peritoneal metastasis of advanced epithelial ovarian carcinoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective international multicentric data analysis

Review Oncology

Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials

P. Filis et al.

Summary: Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with interval cytoreductive surgery (CRS) and neoadjuvant chemotherapy significantly improves overall survival (OS) and disease-free survival (DFS) in primary ovarian cancer.

ESMO OPEN (2022)

Add to Collection

Article Oncology

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial

Francois Quenet et al.

Summary: This study aimed to evaluate the specific benefit of adding hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery compared with receiving cytoreductive surgery alone in patients with colorectal peritoneal metastases. The results showed no significant overall survival benefit after adding HIPEC, with more frequent postoperative late complications, suggesting that cytoreductive surgery alone should be prioritized as a treatment strategy.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial

Tingyan Shi et al.

Summary: In patients with platinum-sensitive relapsed ovarian cancer, secondary cytoreduction followed by chemotherapy significantly prolongs progression-free survival compared to chemotherapy alone. Patients should be informed about the option of secondary cytoreduction in specialized centers.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study

Oliver Zivanovic et al.

Summary: In this study, while HIPEC with carboplatin achieved a higher rate of complete tumor resection, it did not show superior clinical outcomes compared to standard treatment, challenging the use of carboplatin HIPEC during secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology